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Abstract
Background and Purpose: With the aging population, it is becoming increasingly important to identify patients
at risk for postsurgical complications who might be more suited for conservative treatment. We sought to
identify predictors of morbidity after surgical treatment of benign prostatic hyperplasia (BPH) using a large
national contemporary population-based cohort.
Methods: Relying on the American College of Surgeons National Surgical-Quality Improvement Program
(ACS-NSQIP; 2006–2011) database, we evaluated outcomes after transurethral resection of the prostate
(TURP), laser vaporization of the prostate (LVP), and laser enucleation of the prostate (LEP). Outcomes
included blood-transfusion rates, length of stay, complications, reintervention rates, and perioperative mortality.
Multivariable logistic-regression analysis evaluated the predictors of perioperative morbidity and mortality.
Results: Overall, 4794 (65.2%), 2439 (33.1%), and 126 (1.7%) patients underwent TURP, LVP, and LEP,
respectively. No significant difference in overall complications (P= 0.3) or perioperative mortality (P= 0.5)
between the three surgical groups was found. LVP was found to be associated with decreased blood transfusions
(odds ratio [OR]= 0.21; P= 0.001), length of stay (OR= 0.12; P< 0.001) and reintervention rates (OR= 0.63;
P = 0.02). LEP was found to be associated with decreased prolonged length of stay (OR= 0.35; P= 0.01). Men
with advanced age at surgery and non-Caucasians were at increased risk of morbidity and mortality. In contrast,
normal preoperative albumin and higher preoperative hematocrit (>30%) levels were the only predictors of
lower overall complications and perioperative mortality.
Conclusions: All three surgical modalities for BPH management were found to be safe. Advanced age and non-
Caucasian race were independent predictors of adverse outcomes after BPH surgery. In patients with these attributes,
conservative treatment might be a reasonable alternative. Also, preoperative hematocrit and albumin levels represent
reliable predictors of adverse outcomes, suggesting that these markers should be evaluated before BPH surgery.
Introduction
W ith the aging u.s. population, a major concernis the increasing prevalence of urologic conditions in
the elderly. The prevalence of lower urinary tract symptoms
(LUTS) increases significantly with age, increasing from
13% to 14% in the fifth decade of life to 28% to 43% after age
60.1–4 In addition, looking specifically at urinary retention
(UR), a recent population-based study demonstrated that
there has been a significant increase in UR and the need for
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emergent urinary catheterizations from 2006 to 2009.5 Si-
milarly, Groves and associates6 found an increase in acute
UR in men with benign prostatic hyperplasia (BPH). These
trends suggest a growing demographic of men necessitating
surgical intervention for BPH.
Transurethral resection of the prostate (TURP) has long
been considered the primary surgical option for management
of BPH in small to moderately sized prostate glands, with
numerous studies demonstrating improvement in IPSS (In-
ternational Prostate Symptom Score) and urinary flow in
patients post-TURP.7,8 TURP can be associated with signif-
icant morbidity and even mortality, however.9 Complication
and surgical revision rates increase with growing prostate
size.10 Thus, newer endoscopic therapies have been devel-
oped over the past decade.11 Unfortunately, the long-term
data on the efficacy/complications are not available for all
these newer therapies, with holmium laser enucleation of the
prostate (HoLEP) being the only modality to have been
evaluated rigorously. A study by Krambeck and colleagues12
looking at more than 1000 HoLEPs demonstrated short-term
( < 6 months), intermediate term (6–12 months), and long-
term ( > 12 months) mean IPSS of 8.7, 5.9, and 5.3, and
maximum urinary flow of 17.9, 19.5, and 22.7 mL/sec, re-
spectively. As well, the recent publication by Elmansy and
coworkers13 on their 10-year experience with HoLEP with a
mean follow-up of more than 5 years reiterated these results.
Given the aging population (frequently with multiple co-
morbidities) and the lack of complication data on all the
newer techniques, it is important to identify patients who may
be at risk of developing complications from surgical inter-
vention and who may be better served with conservative
treatment. Therefore, we sought to identify the predictors of
morbidity after surgical treatment of BPH using a large na-
tional contemporary population-based cohort of patients. We
hypothesized that newer treatment modalities may have a
protective effect on complication frequency for men other-
wise at increased risk of complications.
Methods
Population source
The current study relied on the American College of
Surgeons National Surgical Quality Improvement Program
(NSQIP) database. Validated data from patients’ medical
charts allows quantification of 30-day, risk-adjusted surgical
outcomes, including postdischarge, when nearly 50% of
complications occur. Trained surgical clinical reviewers pro-
spectively collect the data. In 2011, the ACS-NSQIP included
data from 315 participating sites and more than 442,149 cases.
Study population
Overall, 7,359 men ‡ 18 years of age undergoing a sur-
gical procedure for BPH including TURP (Current Proce-
dural Terminology [CPT] codes: 52601 and 52630), laser
vaporization of the prostate (LVP) (CPT code: 52648) or
laser enucleation and morcellation of the prostate (CPT-code:
52649) between 2006 and 2011 were identified. For the
purpose of this study, because it is not known which laser was
used for which technique, patients who underwent vapor-
ization will be categorized as LVP and those patients who
underwent enucleation will be categorized as laser enucle-
ation of the prostate (LEP). Multiple imputations were used
for the analysis of patients with missing data (n = 4247). In
particular, 51 patients had unknown body mass index (BMI),
23 patients had unknown operative time, and 4247 patients
had unknown preoperative albumin levels.
Covariates
For each patient, age at time of surgery, race, smoking
status, BMI, anesthesia, operative time, and baseline comor-
bidities including diabetes, hypertension, cardiovascular and
‘‘other’’ (baseline dyspnea, chronic obstructive pulmonary
disease, peripheral vascular disease, claudication, esophageal
varices, hemodialysis, history of cerebrovascular accident or
transient ischemic attack, hemiplegia, baseline renal insuffi-
ciency [creatininem > 2 mg/dL]) were evaluated. In addition,
preoperative albumin and hematocrit levels were available.
Outcomes
Postoperative complications were classified under the
following categories: Overall, cardiovascular (including post-
operative cardiac arrest, myocardial infarction, or cerebro-
vascular accident), pulmonary (including pneumonia, need for
postoperative reintubation, and ventilator support > 48 hours),
thromboembolic (including deep venous thrombosis and pul-
monary embolism), sepsis/shock (including systemic sepsis
and septic shock), renal (including acute renal failure and
progressive renal insufficiency), urinary tract infection, and
wound infection (including superficial, deep, and organ-space
surgical site infections, as well as wound dehiscence). Addi-
tional outcomes assessed were the need for reintervention
(within 30 days), blood transfusion, prolonged length of stay
(pLOS) (‡ 2 days), and perioperative mortality.
Statistical analyses
Descriptive statistics of categoric variables focused on
frequencies and proportions. Means, medians, and inter-
quartile ranges were reported for continuous variables.
Univariable logistic regression models tested the associa-
tion between preoperative covariates (including the type of
surgical procedure performed) and the rate of blood trans-
fusions, pLOS, overall complications, and perioperative mor-
tality rates. Multivariable logistic regression models including
only predictors at univariable analyses were then generated.
All statistical tests were performed using the R statistical
package (version 3.0.2), with a two-sided significance level
set at P < 0.05.
Results
Baseline characteristics
Overall, 7359 patients with BPH undergoing surgical
treatment at one of the NSQIP participating hospitals be-
tween 2006 and 2011 were included. Of these, 4794 (65.2%),
2439 (33.1%), and 126 (1.7%) patients underwent TURP,
LVP, and LEP, respectively.
Table 1 displays the baseline characteristics of the cohort.
When men were stratified according to the surgical procedure
they underwent (TURP vs LVP vs LEP), statistically signifi-
cant differences were observed with regard to the age at time of
surgery (P< 0.001), race (P< 0.001), preoperative hematocrit
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value (P= 0.001), anesthetic type (P< 0.001), preoperative
albumin level (P< 0.001), and operative time (P< 0.001). In
particular, men undergoing LEP were significantly less likely
to have a medical comorbidity classified as ‘‘other’’ when
compared with men in the TURP or LVP cohorts. In addition,
a larger percentage of men undergoing LEP had a preopera-
tive hematocrit value > 45% and preoperative serum albumin
level > 3.5 g/dL compared with men undergoing TURP and
LVP. The proportion of patients who underwent TURP under
general anesthesia was significantly higher compared with
Table 1. Descriptive Characteristics of 7359 Patients ‡ 18Years Old Undergoing Either Transurethral
Resection of the Prostate or Tissue Vaporization or Enucleation for Management of Benign Prostatic
Hyperplasia (National Surgical Quality Improvement Program Database 2006–2009)
Variables Overall (%) TURP (%) Tissue vaporization (%) Enucleation (%) P
Number of patients (%) 7359 (100) 4794 (65.2) 2439 (33.1) 126 (1.7) —
Age (years, mean) 71.8 72.2 71.0 69.0 < 0.001
Race; n (%)
Caucasian 5478 (74.4) 3448 (71.9) 1935 (79.3) 95 (75.4) < 0.001
Other 1881 (25.6) 1346 (28.1) 504 (20.7) 31 (24.6)
Smoking; n (%)
Nonsmoker 6565 (89.2) 4264 (88.9) 2194 (89.9) 107 (84.9) 0.125
Smoker 794 (10.8) 530 (11.1) 245 (10.0) 19 (15.1)
BMI; n (%)
< 25 2134 (29.0) 1390 (29.0) 705 (28.9) 39 (31.0) 0.683
25–30 3062 (41.6) 1981 (41.3) 1024 (42.0) 57 (45.2)
> 30 2163 (29.4) 1423 (29.7) 710 (29.1) 30 (23.8)
Preoperative comorbidities
Diabetes; n (%) 1513 (20.6) 1018 (21.2) 471 (19.3) 24 (19.0) 0.146
Hypertension; n (%) 4684 (63.6) 3083 (64.3) 1524 (62.5) 77 (61.1) 0.261
Cardiovascular comorbidities; n (%) 1266 (17.2) 805 (16.8) 445 (18.2) 16 (12.7) 0.121
Other cedical comorbidities; n (%) 1359 (18.5) 881 (18.4) 468 (19.2) 10 (7.9) 0.006
Hematocrit; n (%)
< 30 307 (4.2) 232 (4.8) 73 (3.0) 2 (1.6) 0.001
30–45 5931 (80.6) 3850 (80.3) 1984 (81.3) 97 (77.0)
> 45 1121 (15.2) 712 (14.9) 382 (15.7) 27 (21.4)
Anesthesia; n (%)
General anesthesia 1985 (27.0) 1534 (32.0) 433 (17.8) 18 (14.3) < 0.001
Spinal anesthesia 5374 (73.0) 3260 (68.0) 2006 (82.2) 108 (85.7)
Preoperative albumin; n (%)
< 2.5 109 (3.5) 80 (4.3) 28 (2.3) 1 (2.8) < 0.001
2.5–3.5 687 (22.1) 443 (23.8) 241 (19.9) 3 (8.3)
> 3.5 2316 (74.4) 1339 (71.9) 945 (77.8) 32 (88.9)
Operative time (minutes, mean) 56.9 54.7 57.4 139.4 < 0.001
TURP= transurethral resection of the prostate; BMI= body mass index.
Table 2. Outcomes in 7359 Patients ‡ 18 Years Old Undergoing Either Transurethral Resection
of the Prostate or Tissue Vaporization or Enucleation for Management of Benign Prostatic
Hyperplasia (National Surgical Quality Improvement Program Database 2006–2009)
Variables Overall (%) TURP (%) Tissue vaporization (%) Enucleation (%) P
Number of patients (%) 7359 (100) 4794 (65.2) 2439 (33.1) 126 (1.7) —
Complications
Overall complications; n (%) 472 (6.4) 312 (6.5) 156 (6.4) 4 (3.2) 0.321
Cardiovascular complications; n (%) 21 (0.3) 16 (0.3) 5 (0.2) 0 (0.0) 0.520
Pulmonary complications; n (%) 42 (0.6) 35 (0.7) 7 (0.3) 0 (0.0) 0.042
Thromboembolic complications; n (%) 27 (0.4) 19 (0.4) 8 (0.3) 0 (0.0) 0.712
Sepsis/shock complications; n (%) 69 (0.9) 52 (1.1) 17 (0.7) 0 (0.0) 0.147
Renal failure complications; n (%) 23 (0.3) 18 (0.4) 5 (0.2) 0 (0.0) 0.385
UTI complications; n (%) 368 (5.0) 234 (4.9) 130 (5.3) 4 (3.2) 0.453
Wound complications; n (%) 10 (0.1) 6 (0.1) 4 (0.2) 0 (0.0) 0.838
Need for reintervention; n (%) 138 (1.9) 104 (2.2) 32 (1.3) 2 (1.6) 0.038
Perioperative mortality; n (%) 27 (0.4) 20 (0.4) 7 (0.3) 0 (0.0) 0.543
Blood transfusion; n (%) 109 (1.5) 94 (2.0) 12 (0.5) 3 (2.4) < 0.001
Prolonged length of stay; n (%) 2122 (28.8) 1897 (39.6) 198 (8.1) 27 (21.4) < 0.001
TURP= transurethral resection of the prostate; UTI= urinary tract infection.
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those treated with LVP or LEP. Finally, patients undergoing
LEP had significantly longer operative times.
Unadjusted postoperative complications rates
Table 2 depicts the rates of postoperative complications,
blood transfusions, pLOS, reintervention, and perioperative
mortality. There was no statistically significant difference in
rates of overall complications among the three treatment
groups (P = 0.3). Patients undergoing TURP, however, had
significantly higher rates of pulmonary complications com-
pared with other surgical modalities (P = 0.04). Urinary tract
infections were by far the most frequent complication and
comparable among surgical groups.
Patients undergoing LVP were less likely to need blood
transfusions compared with patients treated with other sur-
gical modalities (P< 0.001). Patients undergoing TURP were
significantly more likely to need subsequent reintervention
and to experience a pLOS (P< 0.04 and P < 0.001, respec-
tively). Finally, no significant difference was observed in
postoperative mortality between the three surgical modalities
(P = 0.5).
Uni- and multivariable logistic regression analyses
Table 3 reports the predictors of morbidity and mortal-
ity after BPH surgery. In multivariate analysis, both age
(odds ratio [OR] = 1.03; P = 0.001) and non-Caucasian race
(OR = 1.55; P= 0.006) were significant predictors of overall
complications (Table 3A). In particular, the odds of experi-
encing overall complications increased by 3% as the age
increased by 1 year (P= 0.001). In contrast, normal preop-
erative albumin levels ( > 3.5 g/dL) were associated with a
lower risk of experiencing overall complications (OR = 0.41;
P = 0.002). Overweight patients (BMI 25–30) (OR = 0.49;
P = 0.03), patients with higher preoperative hematocrits
(30%–45%) (OR = 0.09;P < 0.001), patients undergoing LVP
(OR = 0.21; P = 0.001), and those with normal preoperative
Table 3A. Uni– and Multivariable Logistic Regression Analysis of Predictors
of Complications in 7359 Patients Undergoing Either Transurethral Resection of the Prostate
or Tissue Vaporization or Enucleation for Management of Benign Prostatic Hyperplasia
(National Surgical Quality Improvement Program Database 2006–2009)
Univariable analyses Multivariable analyses
Odds ratio P value Odds ratio P value
Age at procedure 1.03 (1.02–1.05) 0.001 1.03 (1.01–1.04) 0.001
Race
Caucasian 1 (ref ) 1 (Ref )
Other 1.60 (1.31–1.95) 0.006 1.55 (1.13–2.13) 0.006
Smoking
Nonsmoker 1 (Ref ) –
Smoker 0.98 (0.72–1.32) 0.8
BMI
< 25 1 (Ref ) –
25–30 0.93 (0.76–1.18) 0.5
> 30 0.96 (0.75–1.22) 0.8
Properative comorbidities
Diabetes 1.32 (1.07–1.65) 0.01 1.32 (0.98–1.85) 0.06
Hypertension 1.25 (1.03–1.52) 0.02 1.08 (0.78–1.48) 0.6
Cardiovascular 1.33 (1.06–1.68) 0.01 1.08 (0.77–1.53) 0.6
Other 1.65 (1.33–2.04) < 0.001 1.35 (0.99–1.84) 0.07
Hematocrit (%)
< 30 1 (Ref ) 1 (Ref )
30–45 0.36 (0.26–0.50) 0.001 0.72 (0.46–1.14) 0.1
> 45 0.26 (0.17–0.39) 0.001 0.58 (0.30–1.11) 0.2
Anesthesia
General 1 (Ref ) –
Spinal 1.15 (0.91–1.37) 0.3
Surgery
TURP 1 (Ref ) 1 (Ref )
Vaporization 0.98 (0.80–1.19) 0.8 0.99 (0.75–1.33) 0.9
Enucleation 0.74 (0.17–1.28) 0.1 1.38 (0.40–4.73) 0.6
Preoperative albumin (g/dL)
< 2.5 1 (Ref ) 1 (Ref )
2.5–3.5 0.65 (0.37–1.14) 0.1 0.72 (0.40–1.28) 0.2
> 3.5 0.19 (0.12–0.33) 0.001 0.41 (0.23–0.73) 0.002
Operative time 1.00 (0.99–1.00) 0.9 –
BMI= body mass index; TURP= transurethral resection of the prostate.
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albumin levels (OR = 0.56; P = 0.02) were less likely to need
postoperative blood transfusion (Table 3B).
Increasing age (OR=1.01; P<0.001), diabetes (OR=1.23;
P=0.03), presence of other comorbidities (OR= 1.35; P=0.01)
and longer operative time (OR= 1.01; P< 0.001) were all as-
sociated with a pLOS (Table 3C). Moderately/severely obese
patients (BMI > 30) (OR=0.75; P= 0.02), patients with higher
preoperative hematocrits (‡ 30%) (OR=0.30; P< 0.001), those
patients receiving a spinal anesthetic (OR = 0.67; P< 0001),
patients undergoing LVP (OR = 0.12; P < 0.001) or LEP
(OR = 0.35; P= 0.01), and those patients with preoperative
albumin levels between 2.5 and 3.5 g/dL (OR = 0.44; P=
0.001) and > 3.5 g/dL (OR = 0.27; P < 0.001) were all asso-
ciated with a decreased rate of pLOS.
Multivariable analysis for predictors of perioperative
mortality demonstrated that both age (OR = 1.10; P= 0.01)
and other comorbidities (OR = 3.13; P= 0.04) were associ-
ated with increased perioperative mortality. In contrast,
higher preoperative hematocrit (30%–45%) (OR = 0.21; P=
0.01) and preoperative albumin levels > 3.5 g/dL (OR = 0.13;
P= 0.01) were the only significant predictors of lower peri-
operative mortality (Table 3D). Examining reintervention
rates, the only predictor of decreased rate of reinterven-
tion was patients undergoing LVP (OR = 0.63; P = 0.02;
Table 3E).
Discussion
LUTS and UR are common in the aging population.14,15
An epidemiology of LUTS study by Coyne and coworkers15
in 2008 estimated the prevalence of at least one LUTS as
defined by the International Continence Study for at least
‘‘sometimes’’ and ‘‘often’’ at 72.3% and 47.9%, respectively.
Furthermore, with the rightward shift in the population de-
mographics, more men will be presenting with LUTS and/or
UR. In a recent article, Roghmann and colleagues5 demon-
strated that although the number of patients presenting to the
emergency department with LUTS was stable between 2006
Table 3B. Uni- and Multivariable Logistic Regression Analysis of Predictors of Need
for Blood Transfusions in 7359 Patients Undergoing Either Transurethral Resection of the Prostate
or Tissue Vaporization or Enucleation for Management of Benign Prostatic Hyperplasia
(National Surgical Quality Improvement Program Database 2006–2009)
Univariable analyses Multivariable analyses
Odds ratio P value Odds ratio P value
Age at procedure 1.06 (1.04–1.08) < 0.001 1.02 (0.98–1.05) 0.2
Race
Caucasian 1 (Ref ) 1 (Ref )
Other 1.99 (1.35–2.94) 0.001 1.31 (0.71–2.42) 0.4
Smoking
Nonsmoker 1 (Ref ) –
Smoker 0.83 (0.44–1.60) 0.5
BMI
< 25 1 (Ref ) 1 (Ref )
25–30 0.37 (0.24–0.58) 0.001 0.49 (0.25–0.96) 0.03
> 30 0.35 (0.21–0.59) 0.001 0.49 (0.23–1.07) 0.1
Preoperative comorbidities
Diabetes 1.09 (0.69–1.75) 0.7 – 0.4
Hypertension 1.83 (1.18–2.86) 0.01 1.09 (0.57–2.07) 0.8
Cardiovascular 1.22 (0.76–1.96) 0.4 – 0.9
Other 1.61 (1.05–2.47) 0.03 1.03 (0.53–2.01) 0.03
Hematocrit (%)
< 30 1 (Ref ) 1 (Ref )
30–45 0.03 (0.02–0.05) < 0.001 0.09 (0.04–0.15) < 0.001
> 45 0.01 (0.01–0.03) < 0.001 0.00 (0.00–0.00) 0.9
Anesthesia
General 1 (Ref ) –
Spinal 1.07 (0.71–1.64) 0.7
Surgery
TURP 1 (Ref ) 1 (Ref )
Vaporization 0.24 (0.13–0.45) 0.001 0.21 (0.09–0.51) 0.001
Enucleation 1.22 (0.38–3.90) 0.7 1.03 (0.10–10.44) 0.9
Preoperative albumin (g/dL)
< 2.5 1 (Ref ) 1 (Ref )
2.5–3.5 0.30 (0.15–0.63) 0.001 1.00 (0.96–1.01) 0.1
> 3.5 0.08 (0.03–0.16) 0.001 0.56 (0.25–0.65) 0.02
Operative time 1.01 (1.01–1.02) 0.001 1.00 (1.00–1.01) 0.06
BMI= body mass index; TURP= transurethral resection of the prostate.
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to 2009, there was an increased incidence of emergency de-
partment visits associated with adverse events including
catheterization (6.43% increase/year). In addition, a number
of studies have highlighted the possible detrimental impact of
conservative medical management of BPH, leading to ad-
verse events and medical treatment failure.16 That being said,
the ‘‘gold standard’’ surgical treatment for BPH, TURP, is
not an option for some patients because of the morbidity
associated with the procedure. If such patients can be iden-
tified, it is plausible that an alternative surgical option can be
applied, or alternatively, it can be determined that conser-
vative management is the sole and best option.
Several of our findings are noteworthy. In this study, we
demonstrate that the majority of patients (65.2%) underwent
TURP, a third of patients (33.1%) underwent LVP, and the
remaining patients (1.7%) underwent LEP. This is repre-
sentative of the surgical modality of choice for the treatment
of BPH by urologists; most do not perform LEP because of its
steep learning curve.17
Second, our comparative effectiveness assessment of the
competing treatment modalities demonstrates the relative
safety of all three surgical approaches. Specifically, no
significant difference in overall complications or perio-
perative mortality between the three groups was identified.
As well, no difference in postoperative renal function was
identified between the three surgical groups. We corrobo-
rate the results of the meta-analysis by Ahyai and associ-
ates,18 which demonstrated similar morbidity and mortality
between TURP and other minimally invasive BPH treat-
ments. TURP patients in our study did have higher rates of
pulmonary complications. This is likely because signifi-
cantly more TURP patients underwent general anesthesia
compared with other surgical modalities. Moreover, we
demonstrate that LVP is associated with decreased blood
transfusions, pLOS, and reintervention rates. These findings
support previous investigations that reported an association
between potassium titanyl phosphate laser and decreased
length of stay and blood transfusions.19,20 Finally, patients
Table 3C. Uni- and Multivariable Logistic Regression Analysis of Predictors of Prolonged Operative
Stay in 7359 Patients Undergoing Either Transurethral Resection of the Prostate
or Tissue Vaporization or Enucleation for Management of Benign Prostatic Hyperplasia
(National Surgical Quality Improvement Program Database 2006–2009)
Univariable analyses Multivariable analyses
Odds ratio P value Odds ratio P value
Age at procedure 1.03 (1.02–1.03) 0.001 1.01 (1.00–1.02) 0.001
Race
Caucasian 1 (Ref ) 1 (Ref )
Other 1.49 (1.34–1.67) 0.001 0.98 (0.78–1.22) 0.8
Smoking
Nonsmoker 1 (Ref ) –
Smoker 1.00 (0.86–1.18) 0.9
BMI
< 25 1 (Ref ) 1 (Ref )
25–30 0.81 (0.72–91) 0.001 0.92 (0.75–1.22) 0.4
> 30 0.73 (0.64–0.84) 0.001 0.75 (0.59–0.96) 0.02
Preoperative comorbidities
Diabetes 1.29 (1.14–1.46) 0.001 1.25 (1.01–1.55) 0.03
Hypertension 1.11 (1.00–1.23) 0.04 1.00 (0.83–1.22) 0.9
Cardiovascular 1.15 (1.01–1.32) 0.03 1.18 (0.94–1.50) 0.1
Other 1.43 (1.30–1.66) 0.001 1.35 (1.09–1.68) 0.01
Hematocrit (%)
< 30 1 (Ref ) 1 (Ref )
30–45 0.29 (0.17–0.28) < 0.001 0.30 (0.21–0.43) < 0.001
> 45 0.16 (0.12–0.21) < 0.001 0.29 (0.19–0.45) < 0.001
Anesthesia
General 1 (Ref ) 1 (Ref )
Spinal 1.79 (1.61–2.00) < 0.001 0.67 (0.55–0.82) < 0.001
Surgery
TURP 1 (Ref ) 1 (Ref )
Vaporization 0.14 (0.11–0.16) 0.001 0.12 (0.10–0.15) < 0.001
Enucleation 0.41 (0.27–0.64) 0.001 0.35 (0.15–0.79) 0.01
Preoperative albumin (g/dL)
< 2.5 1 (Ref ) 1 (Ref )
2.5–3.5 0.38 (0.25–0.57) 0.001 0.44 (0.27–0.71) 0.001
> 3.5 0.18 (0.12–0.27) < 0.001 0.27 (0.17–0.43) < 0.001
Operative time 1.01 (1.01–1.02) < 0.001 1.01 (1.00–1.01) < 0.001
BMI= body mass index; TURP= transurethral resection of the prostate.
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undergoing LEP had decreased pLOS. Taken together, our
findings suggest that LVP and LEP may be considered as an
alternative treatment modality in patients who are at risk of
adverse events after BPH surgery.
Our analyses reveal important findings with regard to
preoperative risk evaluation. For example, age was an inde-
pendent predictor of three primary end points—namely,
overall complications, perioperative mortality, and pLOS. A
study by Cullen and associates21 corroborates these results in
patients undergoing TURP. They found increasing age to be
associated with increased length of stay and complication
rates. In addition, Jeldres and coworkers22 demonstrated that
age was a significant independent predictor of 30-day mor-
tality after TURP. Similar to age, non-Caucasian race was an
independent predictor of complications after BPH surgery.
While patients of non-Caucasian races often present with
more comorbidities,23 race was nevertheless an independent
predictor of overall complications. These findings confirm
results for other medical conditions, where race predicted the
risk of morbidity and mortality after surgery.24 While bio-
logic hypotheses may be advanced, a worrisome body of
literature has demonstrated that non-Caucasian patients may
not have access to the best care.25 Taken together, these
findings provide important information to guide patient
counseling and decision making.
With regard to serum markers, our study demonstrates the
importance of serum albumin levels for prediction of adverse
events after BPH surgery. Specifically, normal preoperative
levels of albumin were associated with a decreased rate of
blood transfusions, pLOS, overall complications, and, most
importantly, a decrease in perioperative mortality. Indeed,
albumin is correlated with nutritional status and is often
lowered in chronic disease states.26 Therefore, in patients
undergoing BPH surgery, hypoalbuminemia may represent a
poor constitutional state, which would portend increased risk
for perioperative morbidity and mortality. The relationship
between albumin and all cause mortality was previously re-
ported by Goldwasser and colleagues,27 who examined
Table 3D. Uni- and Multivariable Logistic Regression Analysis of Predictors of Need
for Perioperative Mortality in 7359 Patients Undergoing Either Transurethral Resection
of the Prostate or Tissue Vaporization or Enucleation for Management of Benign Prostatic Hyperplasia
(National Surgical Quality Improvement Program Database 2006–2009)
Univariable analyses Multivariable analyses
Odds ratio P value Odds ratio P value
Age at procedure 1.13 (1.06–1.19) < 0.001 1.10 (1.00–1.19) 0.01
Race
Caucasian 1 (Ref ) –
Other 0.66 (0.25–1.75) 0.4
Smoking
Nonsmoker 1 (Ref ) –
Smoker 1.03 (0.31–3.44) 0.9
BMI
< 25 1 (Ref ) 1 (Ref )
25–30 0.16 (0.05–0.48) < 0.001 0.29 (0.06–1.41) 0.1
> 30 0.36 (0.13–0.88) 0.02 0.99 (0.27–3.66) 0.9
Preoperative comorbidities
Diabetes 2.28 (1.04–4.99) 0.04 1.55 (0.49–4.88) 0.4
Hypertension 2.03 (0.81–4.97) 0.1 –
Cardiovascular 1.68 (0.71–4.00) 0.2 –
Other 5.57 (2.60–11.92) < 0.001 3.13 (1.08–9.01) 0.03
Hematocrit (%)
< 30 1 (Ref ) 1 (Ref )
30–45 0.09 (0.01–0.23) 0.001 0.21 (0.07–0.66) 0.01
> 45 0.03 (0.01–0.21) < 0.001 0.00 (0.00–0.00) 0.9
Anesthesia
General 1 (Ref ) –
Spinal 0.94 (0.40–2.24) 0.9
Surgery
TURP 1 (Ref ) 1 (Ref )
Vaporization 0.68 (0.29–1.62) 0.4 1.29 (0.44–3.78)
Enucleation 0.00 (0.00–0.00) 0.9 0.00 (0.00–0.00) 0.9
Preoperative albumin (g/dL)
< 2.5 1 (Ref ) 1 (Ref )
2.5–3.5 0.15 (0.05–0.48) 0.001 0.29 (0.08–1.03) 0.06
> 3.5 0.03 (0.01–0.11) < 0.001 0.13 (0.03–0.59) 0.01
Operative time 0.98 (0.97–1.00) 0.1 –
BMI= body mass index; TURP= transurethral resection of the prostate.
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numerous large population cohort studies and demonstrated a
direct relationship in adjusted analyses between albumin and
decreased mortality. Lambert and associates28 also reported
an increase in overall complications, in overall mortality and
in cancer-specific mortality after cystectomy in patients with
low levels of albumin.
Another important finding is that a preoperative hematocrit
of 30% or more is associated with decreased rates of blood
transfusions and pLOS. While the decreased need for blood
transfusions may be easy to explain, we also show that a
higher hematocrit is associated with a decrease in peri-
operative mortality. Previous investigations have demon-
strated that low hematocrit is associated with chronic
inflammatory disease states and infectious processes and has
also been shown to increase mortality in patients undergoing
hemodialysis.29 Therefore, it is possible that patients with
BPH and low hematocrit have a combination of chronic
prostatic inflammation and lower hemoglobin, which may
place them at risk of perioperative mortality.
Among its many positives, the NSQIP database also has
several drawbacks. First, the lack of hospital and payer
characteristics prevented assessment of the impact of hospital
volume or other socioeconomic factors such as insurance
status on perioperative outcomes. In addition, the voluntary
participation in the NSQIP requires resources, which may
select for larger, high-volume, and academic institutions. As
such, our results may not be generalizable to the broad
medical community.
Second, an important consideration is that identification
of cases for this study was based on CPT codes. Therefore,
this study has limitations inherent to the use of CPT coding
(such as coding errors). In addition, more accurate details
were not available concerning the type of surgery per-
formed. As such, it was not clear whether prostatic laser
vaporization was performed by PVP or by holmium laser.
Moreover, with regards to PVP, during this study period,
only the HPS 120W system was available in North Amer-
ica. As such, outcomes related to the use of the current
Table 3E. Uni- and Multivariable Logistic Regression Analysis of Predictors of Need
for Re–Intervention in 7359 Patients Undergoing Either Transurethral Resection of the Prostate
or Tissue Vaporization or Enucleation for Management of Benign Prostatic Hyperplasia
(National Surgical Quality Improvement Program Database 2006–2009)
Univariable analyses Multivariable analyses
Odds ratio P value Odds ratio P value
Age at procedure 1.02 (1.00–1.04) 0.03 1.01 (0.99–1.02) 0.06
Race
Caucasian 1 (Ref ) –
Other 1.26 (0.85–1.78) 0.3
Smoking
Nonsmoker 1 (Ref ) –
Smoker 1.08 (0.58–1.73) 0.9
BMI
< 25 1 (Ref ) –
25–30 0.89 (0.60–1.32) 0.5
> 30 0.74 (0.49–1.19) 0.3
Preoperative comorbidities
Diabetes 0.76 (0.49–1.21) 0.2 –
Hypertension 0.85 (0.61–1.21) 0.4 –
Cardiovascular 1.01 (0.95–1.58) 0.9 –
Other 0.93 (0.59–1.44) 0.7 –
Hematocrit (%)
< 30 1 (Ref ) 1 (Ref )
30–45 0.36 (0.20–0.64) < 0.001 0.62 (0.42–1.02) 0.08
> 45 0.45 (0.23–0.89) 0.02 0.53 (0.27–1.07) 0.07
Anesthesia
General 1 (Ref ) –
Spinal 0.99 (0.68–1.45) 0.9
Surgery
TURP 1 (Ref ) 1 (Ref )
Vaporization 0.60 (0.40–0.89) 0.01 0.63 (0.42–0.93) 0.02
Enucleation 0.72 (0.17–2.29) 0.7 0.78 (0.19–3.23) 0.7
Preoperative albumin (g/dL)
< 2.5 1 (Ref ) –
2.5–3.5 0.46 (0.16–1.30) 0.1
> 3.5 0.40 (0.15–1.04) 0.06
Operative time 1.00 (1.00–1.06) 0.1 –
BMI= body mass index; TURP= transurethral resection of the prostate.
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180W system cannot be assessed.30 Also, while LEP was
most likely performed using the holmium laser system, it
may also have been performed with other laser modalities
such as thulium and GreenLight,31,32 and also the small
number of LEP procedures performed during the study
period might represent another limitation. As well, it is
unknown what type of TURP was performed—mono vs
bipolar.
Another limitation of this study was the lack of preoper-
ative prostate gland information including serum prostate-
specific antigen level and prostate gland size. Furthermore,
patient use of anticoagulants was not available, which could
have a significant impact on postoperative outcomes—
namely, the need for blood transfusions. Moreover, serum
albumin values were only available for 58% of our patient
population. Therefore, the importance of albumin as a pre-
operative predictor of surgical morbidity needs to be further
evaluated before it can be used in this context.
Finally, it is possible that with the emergence of LVP in
recent years, our data may not provide an accurate depiction
of the most contemporary trends in the surgical treatment of
patients with BPH.
Conclusions
In our analysis of data from the NSQIP initiative, all three
major surgical modalities for treatment of patients with BPH
were found to be safe. Age and race were independent pre-
dictors of adverse outcomes after BPH surgery. In patients
with these attributes, preoperative surgical risk evaluation is
warranted. Finally, preoperative hematocrit and albumin
levels represent reliable serum markers for prediction of
adverse outcomes, suggesting that these markers should be
evaluated before BPH surgery.
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Abbreviations Used
ACS¼American College of Surgeons
BMI¼ body mass index
BPH¼ benign prostatic hyperplasia
HoLEP¼ holmium laser enucleation of the prostate
IPSS¼ International Prostate Symptom Score
LEP¼ laser enucleation of the prostate
LUTS¼ lower urinary tract symptoms
LVP¼ laser vaporization of the prostate
NSQIP¼National Surgical Quality Improvement Program
OR¼ odds ratio
pLOS¼ prolonged length of stay
TURP¼ transurethral resection of the prostate
UR¼ urinary retention
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